POTIGA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTIGA (POTIGA).

How it works

Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.

What the body does with it

Metabolism	Primarily glucuronidation by UGT1A9 and UGT2B7; minor CYP2E1 involvement.
Excretion	Renal excretion accounts for approximately 25-30% of the administered dose as unchanged drug; the remainder is eliminated as metabolites via the biliary/fecal route (up to 70%) and further metabolized. Total recovery in urine and feces is >90%, with fecal excretion being the major route.
Half-life	Terminal elimination half-life is approximately 13-16 hours in healthy individuals, allowing twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged (up to 30 hours).
Protein binding	Approximately 40% bound to albumin, mainly to albumin with minor binding to alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is approximately 0.7 L/kg, indicating distribution into total body water, and is consistent with low tissue binding.
Bioavailability	Oral bioavailability is approximately 90% (due to high absorption with minimal first-pass effect).
Onset of Action	Oral administration: Peak plasma concentrations are achieved in 1-2 hours, with clinical antiepileptic effect typically observed within 1-2 weeks of starting therapy (titration period).
Duration of Action	Duration of action approximately 12 hours (consistent with twice-daily dosing). Steady-state is achieved within 5-7 days. Clinical effect is sustained with regular dosing.

Classification & Brands

Dosing & administration

100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.

Dosage form	TABLET
Renal impairment	For CrCl 30-79 mL/min: 50 mg once daily for 1 week, then 100 mg twice daily; for CrCl 15-29 mL/min: 50 mg once daily for 1 week, then 50 mg twice daily; for CrCl <15 mL/min or hemodialysis: 50 mg once daily with post-dialysis supplementation of 50 mg.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily for 1 week, then 100 mg twice daily; Child-Pugh C: not recommended.
Pediatric use	For children ≥4 years with partial-onset seizures: 1.5 mg/kg/day (maximum 50 mg/day) orally once daily for 1 week, then increase to 3 mg/kg/day (or 100 mg/day) in 2 divided doses for week 2, followed by 4.5 mg/kg/day (or 150 mg/day) in 2 divided doses for week 3, then maintenance of 6 mg/kg/day (or 200 mg/day) in 2 divided doses.
Geriatric use	Start at 50 mg once daily for 1 week, then increase to 50 mg twice daily; consider lower doses due to age-related renal impairment; monitor renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTIGA (POTIGA).

Breastfeeding	No data on excretion in human milk; M/P ratio unknown. Risk of infant sedation, poor feeding, and withdrawal. Caution advised; consider alternative therapies or discontinue breastfeeding.
Teratogenic Risk	POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester: potential for major malformations, but data insufficient. Second and third trimesters: risk of fetal toxicity and neonatal withdrawal. Should only be used if benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to ezogabine or any component","Concurrent use with other potassium channel openers (e.g., retigabine)","Severe hepatic impairment (Child-Pugh C)"]

Clinical Precautions

Precautions

["Neuropsychiatric symptoms (hallucinations, confusion, psychosis)","Increased risk of suicidal thoughts/behavior","QT prolongation (dose-dependent)","Urinary retention","PR interval prolongation","Hepatotoxicity"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTIGA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for POTIGA (POTIGA).

How it works

Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.

What the body does with it

Metabolism	Primarily glucuronidation by UGT1A9 and UGT2B7; minor CYP2E1 involvement.
Excretion	Renal excretion accounts for approximately 25-30% of the administered dose as unchanged drug; the remainder is eliminated as metabolites via the biliary/fecal route (up to 70%) and further metabolized. Total recovery in urine and feces is >90%, with fecal excretion being the major route.
Half-life	Terminal elimination half-life is approximately 13-16 hours in healthy individuals, allowing twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged (up to 30 hours).
Protein binding	Approximately 40% bound to albumin, mainly to albumin with minor binding to alpha-1-acid glycoprotein.
Volume of Distribution	Volume of distribution is approximately 0.7 L/kg, indicating distribution into total body water, and is consistent with low tissue binding.
Bioavailability	Oral bioavailability is approximately 90% (due to high absorption with minimal first-pass effect).
Onset of Action	Oral administration: Peak plasma concentrations are achieved in 1-2 hours, with clinical antiepileptic effect typically observed within 1-2 weeks of starting therapy (titration period).
Duration of Action	Duration of action approximately 12 hours (consistent with twice-daily dosing). Steady-state is achieved within 5-7 days. Clinical effect is sustained with regular dosing.

Classification & Brands

Dosing & administration

100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.

Dosage form	TABLET
Renal impairment	For CrCl 30-79 mL/min: 50 mg once daily for 1 week, then 100 mg twice daily; for CrCl 15-29 mL/min: 50 mg once daily for 1 week, then 50 mg twice daily; for CrCl <15 mL/min or hemodialysis: 50 mg once daily with post-dialysis supplementation of 50 mg.
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily for 1 week, then 100 mg twice daily; Child-Pugh C: not recommended.
Pediatric use	For children ≥4 years with partial-onset seizures: 1.5 mg/kg/day (maximum 50 mg/day) orally once daily for 1 week, then increase to 3 mg/kg/day (or 100 mg/day) in 2 divided doses for week 2, followed by 4.5 mg/kg/day (or 150 mg/day) in 2 divided doses for week 3, then maintenance of 6 mg/kg/day (or 200 mg/day) in 2 divided doses.
Geriatric use	Start at 50 mg once daily for 1 week, then increase to 50 mg twice daily; consider lower doses due to age-related renal impairment; monitor renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for POTIGA (POTIGA).

Breastfeeding	No data on excretion in human milk; M/P ratio unknown. Risk of infant sedation, poor feeding, and withdrawal. Caution advised; consider alternative therapies or discontinue breastfeeding.
Teratogenic Risk	POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester: potential for major malformations, but data insufficient. Second and third trimesters: risk of fetal toxicity and neonatal withdrawal. Should only be used if benefit outweighs risk.

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to ezogabine or any component","Concurrent use with other potassium channel openers (e.g., retigabine)","Severe hepatic impairment (Child-Pugh C)"]